drugset
drugset / Trial / NCT06028464

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood

NCT06028464 ↗

Phase 1 Completed 16 enrolled Boehringer Ingelheim
NaSequentialOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of multiple oral doses of the strong CYP3A inducer carbamazepine on the pharmacokinetics of a single dose of BI 1810631 in plasma.

Timeline

Start
2023-09-11
Primary completion
2023-12-08
Completion
2023-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule 600 mg Oral
Subject Zongertinib Small molecule 60 mg Oral

Indications

No indication recorded.